Global malaria community calls for increased investment in development and scale-up of malaria innovations following R21 vaccine announcement – but RBM Partnership warns “it’s not the only solution”.

Basic childhood immunisation rebounded in 2022, as lower-income countries committed historic levels of domestic funding to immunisation programmes.

Efforts to vaccinate “zero-dose” children in the Democratic Republic of the Congo (DRC) will be accelerated thanks to new funding from Gavi, the Vaccine Alliance’s Equity Accelerator Fund (EAF).

Lower-income countries supported by the Alliance are on the road to recovery, with DTP3 vaccine coverage going up by 3 percentage points.

Through a memorandum of understanding (MoU), the three organizations will work together to coordinate and facilitate the exchange of information, experience and knowledge concerning audit and advisory activities.

Twelve countries across different regions in Africa are set to receive 18 million doses of the first-ever malaria vaccine over the next two years.

Gavi’s Board approved new investments in six-in-one (hexavalent) vaccine and approved a long list of potential new vaccines for consideration for inclusion in future Gavi programmes at its Board Meeting, which concluded today 

The Gavi Board decided today to appoint David Marlow, currently Gavi`s Chief Operating Officer, to the position of Interim Chief Executive Officer, effective 3 August 2023.

The Global Vaccine Impact Conference closed today, as the Vaccine Alliance marked more than 1 billion children vaccinated through its programmes.

Gavi, the Vaccine Alliance, has now facilitated the immunisation of more than one billion children with childhood vaccines.

Global leaders and immunisation experts are coming together to assess the progress of the Vaccine Alliance and discuss the challenges it faces in the future.

Global oral cholera vaccine (OCV) supply could enable large-scale preventive vaccination by 2026 – but urgent action is needed to achieve this goal.